Inhibikase Therapeutics Inc IKT

NAS: IKT | ISIN: US45719W1062   30/04/2025
2,260 USD (+0,44%)
(+0,44%)   30/04/2025

5 oktober 2023 · Thinking about buying stock in Gaucho Group Holdings, Inhibikase Therapeutics, Energy Transfer LP, Longeveron, or Grom Social Enterprises? · Persbericht

24 augustus 2023 · Inhibikase Therapeutics Announces Development of Novel Formulation of risvodetinib · Persbericht

22 augustus 2023 · Inhibikase Therapeutics to Present at the International Congress of Parkinson's Disease and Movement Disorders · Persbericht

21 augustus 2023 · Inhibikase Therapeutics Initiates Development of Second Generation c-Abl inhibitors and names IkT-148009 as risvodetinib · Persbericht

17 augustus 2023 · Inhibikase Therapeutics Announces Completion of the 501 Bioequivalence Study of IkT-001Pro · Persbericht

14 augustus 2023 · Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity · Persbericht

7 augustus 2023 · Inhibikase Therapeutics to Report Second Quarter Financial Results on August 14, 2023 · Persbericht

17 juli 2023 · Inhibikase Therapeutics Regains Compliance with Nasdaq Listing Requirements · Persbericht

29 juni 2023 · Inhibikase Therapeutics Announces a 1-for-6 Reverse Stock Split · Persbericht

22 juni 2023 · Inhibikase Therapeutics Announces Selection of the Bioequivalent Dose of IkT-001Pro and Provides Update on the '501' Bioequivalence Study · Persbericht

21 juni 2023 · Inhibikase Therapeutics Initiates Medical and Patient Awareness Campaign for its Phase 2 '201' Trial Evaluating IkT-148009 in Parkinson's Disease · Persbericht

30 mei 2023 · Inhibikase Therapeutics to Present at the LD Micro Invitational XIII · Persbericht

16 mei 2023 · Inhibikase Therapeutics Announces Dosing of First Patient in its Phase 2 '201' Clinical Trial of IkT-148009 to Treat Parkinson's Disease · Persbericht

15 mei 2023 · Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity · Persbericht

8 mei 2023 · Inhibikase Therapeutics to Report First Quarter Financial Results on May 15, 2023 · Persbericht

4 mei 2023 · Inhibikase Therapeutics to Present at the Sidoti Micro-Cap Virtual Conference · Persbericht

26 april 2023 · Inhibikase Therapeutics Provides Safety and Functional Update on its Phase 1/1b 101 Trial and its Phase 2 IkT-148009 201 Trial in Parkinson's Disease · Persbericht

21 april 2023 · Inhibikase Therapeutics to Present at the 2023 Planet MicroCap Showcase · Persbericht

31 maart 2023 · Inhibikase Therapeutics Reports Full Year 2022 Financial Results and Highlights Recent Period Activity · Persbericht

23 maart 2023 · Inhibikase Therapeutics to Report Fourth Quarter and Full-Year 2022 Financial Results on March 31, 2023 · Persbericht

Mijn selecties